Tag: Daiichi Sankyo

CHMP issues positive opinions for both bempedoic acid and the bempedoic acid / ezetimibe fixed dose combination tablet as treatments for hypercholesterolaemia

Bempedoic acid is an oral, once-daily ATP citrate lyase inhibitor that reduces cholesterol synthesis in the liver. This unique mechanism of action is complementary to statins and other lipid-lowering therapies1 Positive CHMP opinions are based on a global clinical trial programme demonstrating consistent LDL-C lowering across a range of patient […]

Exelixis’ Collaborator Daiichi Sankyo Launches MINNEBRO® (Esaxerenone) Tablets in Japan

ALAMEDA, Calif.–(BUSINESS WIRE)–Exelixis, Inc. (Nasdaq: EXEL) today announced its partner Daiichi Sankyo Company, Limited (“Daiichi Sankyo”) has launched MINNEBRO® (esaxerenone) tablets as a treatment for patients with hypertension in Japan. With Daiichi Sankyo’s first commercial sale of MINNEBRO, Exelixis will receive an associated $20 million milestone payment from Daiichi Sankyo under […]

Data from the Non-interventional EMIT-AF/VTE Study Shows Low Thromboembolic and Bleeding Event Rates in Unselected Elderly AF/VTE Patients on Oral, Once-daily LIXIANA®▼ Undergoing Diagnostic or Therapeutic Procedures

MUNICH, March 19, 2019 /PRNewswire/ — In 2019, the Edoxaban Clinical Research Programme will deliver new evidence on LIXIANA®▼ (edoxaban) use in clinical practice. EMIT-AF/VTE is one of the first sets of data to be presented EMIT-AF/VTE is a large observational, multicentre, multinational study on edoxaban peri-procedural management and outcomes It is […]

Esperion Announces Agreement with Daiichi Sankyo Europe (DSE) to Commercialize Bempedoic Acid in Europe

ANN ARBOR, Mich., Jan. 04, 2019 (GLOBE NEWSWIRE) — Esperion Therapeutics (NASDAQ: ESPR) today announced that they have entered into a licensing agreement with Daiichi Sankyo Europe (DSE) providing DSE with exclusive rights to commercialize bempedoic acid and the bempedoic acid / ezetimibe combination pill in the European Economic Area […]

Daiichi Sankyo Presents First Snapshot Analyses from Global ETNA-AF Programme of Oral, Once-daily LIXIANA®▼ (edoxaban) in Patients with Nonvalvular Atrial Fibrillation in Routine Clinical Practice

MUNICH, Aug. 28, 2018 /PRNewswire/ — The Global ETNA-AF programme is a large and comprehensive single non-vitamin K oral anticoagulant (NOAC) repository of real-world data, as part of the Edoxaban Clinical Research Programme, EDOSURE Three snapshot analyses from baseline data add to growing evidence of the use of edoxaban in the real-world […]

Daiichi Sankyo Initiates ENVISAGE-TAVI AF Study Investigating Once-Daily LIXIANA®▼ (edoxaban) in Patients with Atrial Fibrillation Undergoing Transcatheter Aortic Valve Implantation

MUNICH, April 27, 2017 /PRNewswire/ — ENVISAGE-TAVI AF is the first study to evaluate the effects of a novel oral anticoagulant on clinical outcomes exclusively in atrial fibrillation patients following successful transcatheter aortic valve implantation Study adds to the growing Edoxaban Clinical Research Programme (ECRP) evaluating its use in a […]